IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.

IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results
IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results

NEW DELHI- IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.


Q4 FY23 Financial Highlights

·         Total income for Q4 FY23 stood at Rs. 596 crore as against Rs. 530 crore in Q3 and Rs.579 crore YoY

·         EBITDA for Q4 FY23 at Rs. 104 crore as compared to Rs. 50 crore in Q3 and Rs. 50 crore YoY

·         Net profit for Q4 FY23 at Rs. 65 crore as compared to Rs. 24 crore in Q3 FY23 and Rs. 28 crore YoY


FY23 Financial Highlights

·         Total income for FY23 stood at Rs. 2,243 crore as compared to Rs. 2,216 crore in FY22

·         EBITDA for FY23 at Rs. 252 crore as compared to Rs. 288 crore in FY22

·         Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

Read Also : BharatPe Appoints Nalin Negi as Chief Executive Officer

Q4FY23 Financial Highlights                                          

(Rs in Crore)

Particulars

Quarterly

Yearly

Q4FY23

Q3FY23

% QoQ

Q4FY22

% YoY

FY23

FY22

% YoY

Total Income

595.9

530.1

12.4%

579.4

2.9%

2242.7

2,216.1

1.2%

EBITDA

104.5

49.7

110.3%

50.0

108.8%

252.1

288.3

-12.6%

EBITDA Margin (%)

17.5%

9.4%

á 810 bps

8.6%

á 890 bps

11.2%

13.0%

â 180 bps

PAT

65.3

24.2

169.8%

27.7

135.2%

140.0

165.7

-15.5%

PAT Margin (%)

11.0%

4.6%

á 640 bps

4.8%

á 620 bps

6.2%

7.5%

â 130 bps

Read Also : Delhi's IGI Airport Ranks Among Top 10 Busiest Airports Globally

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalization and margin improvement.

With significant operational, technical, and commercial efficiencies, improved market combination, and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory

Read Also : CBDT signs record number of 125 Advance Pricing Agreements in FY 2023-24